Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Marc Frahm maintained a Buy rating on Scholar Rock (SRRK) on August 7, citing strengthened regulatory pathways for apitegromab and solid cash reserves. The firm highlights de-risked manufacturing options and management's confidence in meeting the September 30 PDUFA date. Barclays also issued a Buy rating with a $55 price target, underscoring an attractive risk-reward profile ahead of the approval decision.
TD Cowen analyst Marc Frahm has maintained their bullish stance on SRRK stock, giving a Buy rating on August 7.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Marc Frahm has given his Buy rating due to a combination of factors, including Scholar Rock’s strengthened regulatory position for apitegromab and solid financial footing. He highlights that the company now has two parallel fill/finish options, with the newly added facility having a clean inspection history and prior support of multiple drug approvals, which together materially de‑risk the path to launch.
He also notes management’s confidence that apitegromab can secure approval by the 9/30 PDUFA date using either facility, despite ongoing timing uncertainty around the FDA’s reclassification decision for the Novo/Catalent site. Combined with a sizable cash balance that can support commercialization and value creation once approval is granted, these elements underpin his view that SRRK’s risk‑reward profile is attractive at current levels.
In another report released on August 7, Barclays also maintained a Buy rating on the stock with a $55.00 price target.